International Journal of Molecular Sciences Article Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma Ángela Marrugal 1, Irene Ferrer 1,2, David Gómez-Sánchez 1,2, Álvaro Quintanal-Villalonga 3, María Dolores Pastor 4, Laura Ojeda 1, Luis Paz-Ares 1,2,5,6,*,† and Sonia Molina-Pinelo 2,4,*,† 1 H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain;
[email protected] (Á.M.);
[email protected] (I.F.);
[email protected] (D.G.-S.);
[email protected] (L.O.) 2 CIBERONC, Respiratory Tract Tumors Program, 28029 Madrid, Spain 3 Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
[email protected] 4 Institute of Biomedicine of Seville (IBIS) (HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain;
[email protected] 5 Medical Oncology Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain 6 Medical School, Universidad Complutense, 28040 Madrid, Spain * Correspondence:
[email protected] (L.P.-A.);
[email protected] (S.M.-P.) † These authors contributed equally to this work. Abstract: Heat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even Citation: Marrugal, Á.; Ferrer, I.; though responses to them have been limited to date. Given the need to maximize treatment efficacy, Gómez-Sánchez, D.; the objective of this study was to use isobaric tags for relative and absolute quantitation (iTRAQ)- Quintanal-Villalonga, Á.; Pastor, based proteomic techniques to identify proteins in human lung adenocarcinoma cell lines whose M.D.; Ojeda, L.; Paz-Ares, L.; basal abundances were correlated with response to HSP90 inhibitors (geldanamycin and radicicol Molina-Pinelo, S.